- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2017-10-06 18:37:34
- Reporting Period:
- Accepted Time:
- 2017-10-06 18:37:34
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|1501989||Cytomx Therapeutics Inc.||CTMX||Pharmaceutical Preparations (2834)||273521219|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1654058||A. Sean Mccarthy||151 Oyster Point Blvd. |
South San Francisco CA 94080
|President And Ceo||Yes||Yes||No||No|
Reported Non-Derivative Transactions
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
Reported Derivative Transactions
|Sec. Name||Sec. Type||Acquisiton - Disposition||Date||Amount||Price||Amount - 2||Price - 2|
|Common Stock||Common Stock||Disposition||2017-10-04||19,120||$0.00||19,120||$0.95|
|Remaning Holdings||Exercise Date||Expiration Date||Equity Swap Involved||Transaction Form Type||Transaction Code||Nature of Ownership|
Reported Non-Derivative Holdings
|Sec. Name||Remaning Holdings||Nature of Ownership||Explanation|
|Common Stock||158,737||Indirect||See footnote|
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.51 to $24.39, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Held in McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees.
- 100% of the shares subject to the option are fully vested and exercisable.
- Previous Form 4s filed by the Reporting Person included an error in the number of securities beneficially owned by the Reporting Person in Table II, Box 9. The number of derivative securities beneficially owned as reported in Table II, Box 9 of this Form 4 has been adjusted to correct the previous errors and reflects the current number of derivative securities beneficially owned as of this filing date.